I want to believe you, however that SEC filing on 11/14/12 was a CT order - (I had to go to investopedia to for those that don't know what is) - and is common on ISIS filings.
There is a short squeeze pending, i'm sure most will agree on that. With over 12 mil shares short (12%) and ISIS so close to it's 52 week lows with several milestones and drugs working it's way through the pipeline... it's just a matter of pressure and time. With an infinite amount of money I would have added to my position as it dropped below $10 and layered the buying down to $6.
But I don't.
Look at dates 10/11/12 - 10/09/12 - 09-11-12 and a person can see the same thing.
Mixing that information with unofficial third party (biopharmcatalyst) that says 11/15/12 is the estimated day is dangerous to throw into the wild.
That said, I've been following ISIS for over 5 years, I have been slowly adding to my position and trading chart patterns when followed probable patterns. This is a winner, Sometimes when I stock drops like this, it's not a loss it's a time to buy MORE! It is however not for the faint of heart.
DISCLOSURE: I have sold my entire position and moved into options with money held back. I believe the EMA and the FDA will move to approve, but if they don't ISIS could drop below $3. Do your homework.
agree to most, but drop to 3 is a bit harsh. They have a lot of cash. Somewhere in the mix, with the strength of their partnerships, they would be vulnerable to take over, like HGSI. While the US shorts itself into oblivion, foreign corporations scoop out bargains and laugh at our system.
PS Kynamro's sales projections after approval are not all that exciting. I think its the long term, the ability to bring more products until one hits home, that creates the real value. Kynamro just underscores the antisense potential underneath. And how big pharma is already in there, dominating the scene.
First, ISIS should receive European approval by year end. Remember this application addresses larger markets as they are seeking approval to treat both HoFN and HeFN, the latter being a much larger market opportunity.
Following European approval we expect FDA approval on or before the PDUFA data of January 29th. ISIS is a buy under $12.